Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab in Previously Treated Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study S1400A)
NCT02766335Phase 3Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2014
- Primary completion
- Sep 2018
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab in squamous cell carcinoma of the lung (SCCL), sponsored by SWOG Cancer Research Network. Started Jul 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT02766335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02766335.